Please try another search
For the three months ended 31 March 2020, Biotoscana Investments SA revenues decreased 2% to R$146.2M. Net loss totaled R$52.4M vs. income of R$8M. Revenues reflect Orphan Drugs & Rare Diseases segment decrease of 22% to R$14.3M, Oncology & Onco-Hematology segment decrease of 5% to R$71.7M, Brazil segment decrease of 29% to R$51.8M, Ecuador segment decrease of 47% to R$2.2M.
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 146.23 | 199.99 | 190.09 | 204.31 |
Gross Profit | 61.28 | 88.03 | 90.06 | 93.14 |
Operating Income | -11.47 | 5.55 | 22.49 | 21.31 |
Net Income | -52.42 | -26.38 | 12.09 | 7.89 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 1411.27 | 1246.95 | 1322.23 | 1243.8 |
Total Liabilities | 599.7 | 506.39 | 561.39 | 479.27 |
Total Equity | 811.57 | 740.56 | 760.84 | 764.53 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -52.72 | 56.11 | 37.51 | 2 |
Cash From Investing Activities | -17.48 | -42.55 | -33.2 | -30.31 |
Cash From Financing Activities | 69.24 | -67.89 | -26.34 | -23.39 |
Net Change in Cash | 4.35 | -52.63 | -22.99 | -48.15 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review